Related Experiment Video
Updated: Oct 8, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.6K
Microsatellite instability-high is rare events in refractory pediatric solid tumors
Taro Yoshida1, Hideki Muramatsu1, Manabu Wakamatsu1
1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Pediatric Hematology and Oncology
|December 29, 2021
Summary
Microsatellite instability-high (MSI-high) status is rare in pediatric solid tumors. This study found no MSI-high cases among 36 patients with refractory/relapsed disease, suggesting limited potential for immune checkpoint inhibitor therapy in this population.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Microsatellite instability-high (MSI-high) status predicts response to immune checkpoint inhibitors.
- While investigated in pediatric brain tumors, MSI-high status in other pediatric solid tumors remains understudied.
Purpose of the Study:
- To investigate the prevalence of MSI-high status in pediatric patients with refractory or relapsed solid tumors.
- To assess the potential utility of immune checkpoint inhibitors in this patient group.
Main Methods:
- Retrospective analysis of formalin-fixed paraffin-embedded tumor tissues from 36 pediatric patients with solid tumors who died of disease.
- MSI status was assessed using five multiplexed markers.
Main Results:
- None of the analyzed patients exhibited MSI-high status.
- The prevalence of MSI-high status in this cohort of pediatric refractory/relapsed solid tumors was 0%.
Conclusions:
- MSI-high status is a rare event in pediatric patients with refractory/relapsed solid tumors.
- This finding suggests that immune checkpoint inhibitor therapy may have limited efficacy in this specific patient population.
